Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan
ConclusionsSix- or 8-week vonoprazan treatment still seems to be insufficient for healing IPUs. Longer-term vonoprazan or another treatment option may be required to heal potentially refractory peptic ulcers.
CONCLUSION: Over the 23 years studied, the causes of NVUGB changed, probably because the population was increasingly elderly population and because of the use of anticoagulants and better therapeutic approaches to chronic duodenal ulcers. The use of emergency surgical hemostasis reduced, but mortality rate did not significantly change between the two specific periods. PMID: 31258140 [PubMed - as supplied by publisher]
We report a case of benign gastric ulcer with EBV infection confirmed by endoscopic and histological findings. PMID: 31013561 [PubMed - in process]
Conclusion: Our present study indicated, for the first time, that ABS could act against H. pylori. ABS is clinically used for the management of GI bleeding due to benign and malignant GI lesions. Thus, the possible anti-H. pylori effect of ABS shall expand the therapeutic spectrum of the drug in GI lesions in relation to H. pylori infection such as peptic ulser disease (PUD) and lymphoid tissue (MALT) lymphomagenesis. PMID: 30761849 [PubMed - in process]
Publication date: March 2019Source: Biomedicine &Pharmacotherapy, Volume 111Author(s): Raquel de Cássia dos Santos, Flavia Bonamin, Larissa Lucena Périco, Vinícius Peixoto Rodrigues, Ana Caroline Zanatta, Clenilson Martins Rodrigues, Miriam Sannomiya, Matheus Aparecido dos Santos Ramos, Bruna Vidal Bonifácio, Taís Maria Bauab, Jorge Tamashiro, Lúcia Regina Machado da Rocha, Wagner Vilegas, Clelia Akiko Hiruma-LimaAbstractByrsonima intermedia is a species of bush popularly used to treat gastrointestinal disorders, such as gastric ulcers, gastritis, and diarrhea. Previous studies...
Conclusion: Biliary reflux and alcohol consumption, but not Helicobacter pylori infection or gastrotoxic drug, seem to be the most important predictors for ulcer recurrence in patients with gastric surgery for peptic ulcer after more than 15 years. PMID: 30524477 [PubMed]
Abstract CASE PRESENTATION: A 57-year-old man was admitted for 1 month of accelerating hemoptysis and hematemesis. Two weeks earlier, he first presented with fevers and hemoptysis of 2 weeks' duration and was diagnosed with community-acquired pneumonia treated with 5 days of ceftriaxone and azithromycin. He improved and was discharged, but his hemoptysis recurred 1 day after discharge and progressed over 9 days, leading to the present admission. He endorsed an 5-kg weight loss, daily fevers up to 39.4°C, and night sweats since discharge. His medical history was significant for peptic u...
Conclusions: This study suggests that GPUs are strongly associated with H. pylori infection in Chinese children. Duodenal ulcers are the main type of GPU in patients older than 6 years. Appropriate diagnosis, treatment and follow-up are necessary for children with GPUs.
ConclusionsThe results support the premise that stroke may be associated with a history ofH pylori infection.
CONCLUSION: Our finding supports previous reports on the damaging effect of environmental noise on the gastrointestinal tract and suggests that cumulative exposure to environmental nighttime noise affects the development of peptic ulcers. PMID: 30366660 [PubMed - as supplied by publisher]
Abstract INTRODUCTION: The introduction of proton pump inhibitors (PPIs) into clinical practice has greatly improved our therapeutic approach to acid-related diseases for their efficacy and safety. Areas Covered:The following evidence-based indications for PPI use are acknowledged by many scientific societies: treatment of the various forms and complications of gastroesophageal reflux disease, eradication of H. pylori infection in combination with two or more antibiotics, short- and long-term therapy of H. pylori-negative peptic ulcers, healing and prevention of NSAID/COXIB-associated gastric ulcers, co-therapy wi...